NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee A) meeting minutes

 **Minutes:** Confirmed

**Date and time:** Wednesday 7 April 2021, 9:30am – 18:18pm

**Location:** via Zoom

## Attendees

Committee members present:

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Professor Abdallah Al-Mohammed Present for all items
4. Mr Peter Baker Present for items 1 to 6.1.3.
5. Mr Richard Ballerand Present for all items
6. Dr Andrew Champion Present for all items
7. Dr Justin Daniels Present for all items
8. Dr Steve Edwards Present for all items
9. Dr Rita Faria Present for all items
10. Dr Michael Holmes Present for all items
11. Ms Sumithra Maheswaran Present for items 1 to 6.1.3
12. Professor G.J. Melendez-Torres Present for items 1 to 3 and 5 to 7
13. Ms Sarah Parry Present for all items
14. Ms Becky Pennington Present for all items
15. Mr Dominic Pivonka Present for all items
16. Ms Pamela Rees Present for all items
17. Dr Stephen Sharp Present for items 1 to 3
18. Dr Alice Turner Present for all items

NICE staff present:

Meindert Boysen, Centre Director Present for items 4.1.3 and 5 and 6

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for items 1 to 3, 4.1 and 5 to 7

Carl Prescott, Technical Advisor Present for items 1 to 3

Marcela Haasova, Technical Analyst Present for items 1 to 3

Mary Hughes, Technical Advisor Present for item 4

Albany Meikle, Technical Analyst Present for item 4

Joanna Richardson, Technical Advisor Present for items 5 to 7

George Braileanu, Technical Analyst Present for items 5 to 7

Emily Eaton Turner, HTA Adviser Present for items 5 to 7

Claire Hawksworth, Evidence Generation Present for item 4

Stevie Okoro, Technical analyst - Commercial risk Present for items 5 to 7

Sarah Bromley, Senior Medical Editor Present for items 5 to 7

Emilene Coventry, Senior Medical Editor Present for items 1 to 3

Hayley Garnett, Senior Medical Editor Present for item 4

Adam Storrow, Resource Impact Team Present for all items

Laura Marsden, Public Involvement Advisor Present for items 1 to 3.1, 4.1 and 5 to 7

Catherine Pank, Assistant Project Manager Present for items 5 to 7

Lucinda Evans, Coordinator Present for item 4.1

Rosalee Mason, Coordinator Present for items 5 and 6.1

Sandra Robinson, Coordinator Present for items 1 to 3.1 and 5 to 7

Mira Patel, Coordinator Present for all items

Gemma Smith, Coordinator Present for item 4

Sophie McHugh, Administrator Present for item 4

Marcia Miller, Administrator Present for items 1 to 3 and 5 to 7

Daniel Greenwood, Assistant Administrator Present for item 4

Professional experts present:

Dr Jason Dunn, Consultant Gastroenterologist, Guy’s & Present for item 3.1

 St Thomas’ Hospitals NHS Foundation Trust,

 nominated by British Society of Gastroenterology

Ms Hannah Hunter, Specialist Allergy Dietitian, Guy’s and Present for items 1 to 3.1

 St Thomas’ NHS Foundation Trust, nominated by

 British Society for Allergy & Clinical Immunology

Dr Jack Winter, Consultant Gastroenterologist, Glasgow Present for items 1 to 3.1

 Royal Infirmary, nominated by Dr Falk Pharma

Ms Amanda Cordell, Cofounder and Chair, EOS Network, Present for items 1 to 3.1

 nominated by EOS Network

Professor Peter Clark, CDF Clinical Lead, NHSE&I Present for item 4

Dr Graham Collins, Haematology Consultant and Present for item 4.1

 Lymphoma Lead, Oxford University Hospitals,

 nominated by MSD

Dr Elizabeth Phillips, Senior Clinical Lecturer and Present for item 4.1

 Honorary Consultant Haematologist, University of

 Manchester and The Christie Hospital, nominated by

 Royal College of Physicians

Mr Stephen Scowcroft, Director of Operations and External Present for item 4.1

 Affairs at Lymphoma Action, nominated by Lymphoma

 Action

Dr Robin Lachmann, Consultant in Metabolic Medicine, Present for items 5 to 7

 UCLH, nominated by Royal College of Physicians

Ms Claire Foreman, Head of Acute Programmes, Present for items 5 to 7

 Specialised Commissioning, NHSE&I

Professor Anita MacDonald, Consultant Dietitian, Birmingham Present for items 5 to 7

 Children’s Hospital, nominated by The National Society

 for Phenylketonuria

Ms Sharon Buckley, patient advocate, nominated by Present for items 5 to 7

 The National Society for Phenylketonuria

External group representatives present:

Keith Cooper, Senior Research Fellow, Southampton Present for items 1 to 3.1.3

 Health Technology Assessments Centre

Jonathan Shepherd, Principal Research Fellow, Present for item 3.1.3

 Southampton Health Technology Assessments Centre

G.J. Melendez-Torres, Professor of Clinical and Social Present for item 4.1

 Epidemiology (Director of PenTAG), [PenTAG](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419)

Brian O’Toole, Research Fellow, [PenTAG](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419) Present for item 4.1

James Mahon, Health Economist, Liverpool Reviews Present for items 5 to 7

 and Implementation Group

Janette Greenhalgh, Senior Research Fellow, Liverpool Present for items 5 to 7

 Reviews and Implementation Group

Observers present

Elizabeth Bell, Technical Analyst, NICE Present for items 1 to 3

Summaya Mohammed, Technical Analyst, NICE Present for item 4.1

Catherine Parker, Technical Analyst, NICE Present for items 1 to 3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Rishi Hazarika, Professor Khalida Ismail, Dr Mohit Sharma, Mr Min Ven Teo and Dr Roger Whittaker.

### News and announcements

* 1. None.

### Appraisal of Budesonide for treating active eosinophilic oesophagitis [ID1202]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Dr Falk Pharma.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Jason Dunn, clinical expert, declared a direct financial interest as he partners with One Welbeck Digestive Health. Prior to the meeting, Dr Dunn, declared a direct financial interest as he received an educational grant from Dr Falk Pharma in order to attend United European Gastroenterology Week in October 2019. Dr Dunn also declared an indirect financial interest as his institution received an educational grant for £3000 from Dr Falk Pharma in September 2019, to fund an event (including organisational and speaker fees) for St Thomas Upper GI Day. It was agreed that these declarations would not prevent Dr Dunn from providing expert advice to the committee.
* Dr Jack Winter, clinical expert, declared a direct financial interest as he participated in paid advisory boards related to Eosinophilic oesophagitis for Dr Falk Pharma in 2017 and 2018. Prior to the meeting, Dr Winter declared a direct financial interest as he received educational sponsorship from Dr Falk Pharma to attend a conference on Eosinophilic Oesophagitis in October 2017. It was agreed that these declarations would not prevent Dr Winter from providing expert advice to the committee.
* Ms Amanda Cordell, patient expert, declared indirect financial interests as her employer, EOS Network, received honoraria from Dr Falk Pharma in February 2021, in order to provide a patient/HC experience presentation on Food Bolus Obstruction for a focus group developing medical education tools for EoE Food Obstruction in A&E. EOS Network has also received honoraria from other pharmaceutical companies including AstraZeneca and Avir Pharma. Prior to the meeting, Ms Cordell declared an indirect interest as EOS Network have access to patient and doctor videos developed by Dr Falk Pharma which educates about EoE. It was agreed that these declarations would not prevent Ms Cordell from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
	+ 1. The Chair introduced the lead team, Dr Andrew Champion, Dr Stephen Sharp and Mr Richard Ballerand, who gave presentations on the clinical effectiveness and cost effectiveness of Budesonide for treating active eosinophilic oesophagitis [ID1202].
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from MSD.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Ms Becky Pennington, committee member, declared a direct financial interest as she currently receives consultancy fees for working on a methods research project for Takeda, the manufacturer of a comparator drug. The project started in January 2021 and is expected to conclude in July 2021. The project is not specific to any Takeda product or indication, including Hodgkin lymphoma. It was agreed that this declaration would not prevent Ms Pennington from participating in this section of the meeting.
* Prior to the meeting, Mr Dominic Pivonka, committee member, declared an indirect interest as his employer, AbbVie, has treatments being investigated in early phase studies for haematologic and solid tumours. These are not yet licensed. AbbVie has licensed and late-stage treatments in an unrelated haematologic cancers. It was agreed that this declaration would not prevent Mr Pivonka from participating in this section of the meeting.
* Prior to the meeting, Dr Alice Turner, declared a direct non-financial professional interest as she currently has a grant undergoing contract with MSD in an unrelated disease area (refractory chronic cough; RCC). Dr Turner is also acting as UK co-ordinating investigator on a trial for MSD in RCC. In both cases, payments go to Dr Turner’s institution. It was agreed that this declaration would not prevent Dr Turner from participating in this section of the meeting.
* Dr Graham Collins, clinical expert, declared direct financial interests as he received honoraria from MSD over 2 years ago for consultancy work. Prior to the meeting, Dr Collins declared further direct financial interests as received honoraria from Takeda for advisory and speaker work. Dr Collins also declared indirect interests as MSD provided him with research support and drugs free of charge for the clinical trial he was running. It was agreed that these declarations would not prevent Dr Collins from providing expert advice to the committee.
* Prior to the meeting, Mr Stephen Scowcroft, patient expert, declared an indirect interest as his employer, Lymphoma Action, receives grant funding from a number of pharmaceutical organisations to support information and education activities. No organisation has any direct editorial into Lymphoma Action’s activities. It was agreed that this declaration would not prevent Mr Scowcroft from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
	+ 1. The Chair introduced the lead team, Dr Alice Turner, Ms Becky Pennington and Ms Pamela Rees, who gave presentations on the clinical effectiveness and cost effectiveness of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557].
	1. Part 2 – Closed session (company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Minutes from the last meeting

5.1. The committee approved the minutes of the committee meeting held on 2 March 2021.

### Appraisal of Sapropterin for treating phenylketonuria [ID1475]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from BioMarin.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Anita MacDonald, clinical expert, declared indirect interests as Birmingham Children's Hospital PKU research fund received consultancy fees from Meta Healthcare, Arlo, Nutricia, Apr, Galen and Biomarin. Birmingham Children’s Hospital also received research funds from Nutricia, Vitaflo, Biomarin, APR, Metax, Galen, Mevalia. It was agreed that these declarations would not prevent Professor MacDonald from providing expert advice to the committee.
* Dr Robin Lachmann, clinical expert, declared a direct financial interest as he has an ongoing consultancy agreement with Biomarin to provide input to their PKU gene therapy programme. Dr Lachmann also declared an indirect interest as his institution receives funding from Nutricia. Prior to the committee meeting, Dr Lachmann declared a direct financial interest as he is receiving consulting fees from Nestle Health Science regarding their PKU programme (ongoing). It was agreed that these declarations would not prevent Dr Lachmann from providing expert advice to the committee.
* Prior to the meeting a patient expert declared an indirect interest and it was agreed that this declaration would not prevent them from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
	+ 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
		2. The Chair announced the meeting was to be adjourned. The meeting for this appraisal will continue at a date which is to be confirmed.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Thursday 6 May 2021 and will start promptly at 9:30am.